Immunosuppressive therapy in high-risk transplant patients: Dose- dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients

Transplantation

Volumn 64, Issue 9, 1997, Pages 1277-1282

  Neylan, John F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; DATA ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECIPIENT; TREATMENT FAILURE; TREATMENT PLANNING;

ADRENAL CORTEX HORMONES; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AZATHIOPRINE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0030716882     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199711150-00008     Document Type: Article

References (37)

1. Opelz G, Mickey MR, Terasaki PI. Influence of race on kidney transplant survival. Transplant Proc 1977; 9: 137.
2. Cicciarelli J. Living donor kidney transplants. In: Terasaki P, ed. Clinical transplants 1988. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1988: 293.
3. Ojo AO, Port FK, Held PJ, et al. Inferior outcome of two-haplo-type matched renal transplants in blacks: role of early rejection. Kidney Int 1995; 48: 1592.
4. Knechtle SJ, Castle DC, Seigler HF, Bollinger RR. Renal transplantation and the American black. Transplant Proc 1989; 21: 3931.
5. Cosio FG, Dillon JJ, Falkenhain ME, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995; 47: 1136.
6. Koyama H, Cecka JM, Terasaki PI. Kidney transplants in black recipients: HLA matching and other factors affecting long-term graft survival. Transplantation 1994; 57: 1064.
7. Dunn J, Vathsala A, Golden D, et al. Impact of race on the outcome of renal transplantation under cyclosporine-prednisone. Transplant Proc 1989; 21: 3946.
8. Gaston RL, Hudson SL, Deierhoi MH, et al. Improved survival of primary cadaveric renal allograft in blacks with quadruple immunosuppression. Transplantation 1992; 53: 103.
9. Bumgardner GL, Roberts JP. New immunosuppressive agents. Adv Liver Transplant 1993; 22: 421.
10. Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993; 12: S2765.
11. Sollinger HW. Update on preclinical and clinical experience with mycophenolate mofetil. Transplant Proc 1996; 28 (suppl 1): 24.
12. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunother 1993; 14: 353.
13. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 1993; 685: 309.
14. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
15. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
16. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C for the International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 1.
17. Solez K, Axelson RA, Benediktsson H, et al. International standardisation of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
18. Barger BO, Hudson SL, Shroyer TW, et al. Influence of race on renal allograft survival in the pre- and postcyclosporine era. In: Terasaki P, ed. Clinical transplants 1987. Los Angeles: UCLA Tissue Typing Laboratory, 1987: 217.
19. Hardy S, Cicciarelli J. Living-related donor kidney transplants. In: Terasaki P, ed. Clinical transplants 1989. Los Angeles: UCLA Tissue Typing Laboratory, 1989: 343.
20. Milgrom M, Gharagozioo H, Gomez C, et al. Results of renal transplantation in Miami analyzed by race. Transplant Proc 1989; 21: 3934.
21. Opelz G, Wujciak T, Schwartz V, Back D, Mytilineos J, Scherer S. Collaborative Transplant Study analysis of graft survival in blacks. Transplant Proc 1993; 25: 2443.
22. Sommer BG, Sing DE, Henry ML, Ferguson RM. The influence of race on renal allograft survival: a single institution analysis. Transplant Proc 1989; 21: 3929.
23. Bia MJ, Ramos EL, Danovitch GM, et al. Evaluation of living renal donors. Transplantation 1995; 60: 322.
24. Callender CO. The results of transplantation in blacks: just the tip of the iceberg. Transplant Proc 1989; 21: 3407.
25. First MR, Schroeder TJ, Carey MA, Chavinson DS. Effect of race on transplant outcome and response to OKT3 monoclonal antibody therapy. Transplant Proc 1989; 21: 3949.
26. McDonald JC. Comment: issues related to race in transplantation. Transplant Proc 1989; 21: 3411.
27. Moosa MR, Grobbelaar C, Swanevelder SA, Edelstein CL. The influence of race and the impact of socioeconomic and clinical factors on primary renal allograft survival. Transplant Proc 1992; 24: 1754.
28. Garvin PJ, Castenada M, Codd JE, Mauller K. Recipient race as a risk factor in renal transplantation. Arch Surg 1983; 118: 1441.
29. Galla JH. IgA nephropathy. Kidney Int 1995; 47: 377.
30. Tornatore KM, Biocevich DM, Reed K, Tousley K, Singh JP, Venuto RC. Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation 1995; 59: 729.
31. Opelz G for the Collaborative Transplant Study. Kidney transplants in black recipients: HLA matching and other factors affecting long-term graft survival. Transplantation 1995; 60: 1220.
32. Terasaki PI, Cecka JM, Eds. Clinical transplants 1995. Los Angeles: UCLA Tissue Typing Laboratory, 1995: 379.
33. Lindholm A, Welsh M, Rutzky L, Kahan BD. The adverse impact of high cyclosporine clearance rates on the incidences of acute rejection and graft loss. Transplantation 1993; 55: 985.
34. First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis JJ, Armenti VT. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transpl 1996; 10: 55.
35. Lindholm A, Ohlman S, Albrechtson D, Tufveson G, Persson M, Persson NH. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by three cyclosporin regimens. Transplantation 1993; 56: 307.
36. Tesi RJ, Henry ML, Elkammas EA, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transpl 1993; 7: 345.
37. Troppmann C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. Transplantation 1995; 59: 962.